PARIS—Ozarelix, an investigational agent, may be effective for selected men with lower urinary tract symptoms (LUTS) associated with BPH, phase II trial data suggest. The drug is a highly soluble luteinizing hormone releasing antagonist.
PARIS—Robot-assisted laparoscopic radical prostatectomy (RALP) for localized prostate tumors is associated with a relatively low positive margin rate, data show.
PARIS—Dutasteride is more effective than tamsulosin for treating men with moderate-to-severe urinary symptoms of BPH, data suggest.
PARIS—Zoledronic acid reduces the risk of a first skeletal-related event (SREs) in patients with early malignant bone disease associated with hormone-refractory prostate cancer (HRPC).
PARIS—Men with lower urinary tract symptoms (LUTS) associated with BPH may benefit more from a combination of tolterodine extended-release and tamsulosin than from either medication alone.
